2020 Excellence in Oncology Award
Winner: Subcutaneous Treatment vs. IV Infusion for HER2-Positive Breast Cancer
Antoinette R. Tan, MD, MHSc, Chief of Breast Medical Oncology, Co-Director of the Phase I Program, and Full Professor of Medicine at Levine Cancer Institute at Atrium Health, has been recognized for her study demonstrating the efficacy and safety of a significantly faster and less-invasive alternative to intravenous infusion of two medicines used to treat HER2-positive breast cancer..
First Runner-Up: Pioneering a New CAR Design Targeting Glioblastoma
Lead author: Christine Brown, the Heritage Provider Network Professor in Immunotherapy and Deputy Director of T Cell Therapeutics Research Laboratories at City of Hope in Duarte, Calif.
Second Runner-Up: STORM Trial Advances Selinexor + Dexamethasone for Multiple Myeloma
Lead author: Maria Gavriatopoulou, MD, PhD, Assistant Professor in the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital in Greece
Honorable Mention: Immunotherapy Safe in Urothelial Carcinoma Patients Often Excluded
Lead author: Cora N. Sternberg, MD, FACP, Clinical Director of the Caryl and Israel Englander Institute for Precision Medicine and Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine.
Honorable Mention: Treatment for Naive Unilateral Unifocal Rentinoblastoma
Lead author: Sonia De Francesco, MD, research scientist at the Unit of Ophthalmology and Rentinoblastoma Referral Center of the Department of Surgery at the University of Siena, Policlinico "Santa MariaalleScotte," Siena, Italy.